Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review

The Impact of Hypoglycemia on the Cardiovascular System

(2016) Shi-Wei Yang et al.   ANGIOLOGY

Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia

(2016) Ambika Amblee et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control

(2016) Robert G. Moses et al.   Journal of Diabetes

Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes

(2016) Seon-Ah Cha et al.   Diabetes & Metabolism Journal

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

(2015) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

(2015) R. S. Weinstock et al.   DIABETES OBESITY & METABOLISM

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study

(2014) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study

(2013) H. Yki-Jarvinen et al.   DIABETES CARE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study

(2013) R. R. Henry et al.   DIABETES OBESITY & METABOLISM

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

(2013) O. J. Phung et al.   DIABETIC MEDICINE

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes

(2013) J. Rosenstock et al.   DIABETIC MEDICINE

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

(2013) Burkhard Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus

(2012) Harshal R. Patil et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

(2012) K. H. Yoon et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial

(2012) Robert Frederich et al.   Diabetology & Metabolic Syndrome

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*

(2012) Adrian S. DOBS et al.   Journal of Diabetes

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

(2011) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks

(2011) Antonio R Chacra et al.   Diabetes & Vascular Disease Research

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

(2011) Priscilla L Hollander et al.   Diabetes & Vascular Disease Research

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

(2011) A. Pfützner et al.   DIABETES OBESITY & METABOLISM

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

(2011) A. H. Barnett   DIABETES OBESITY & METABOLISM

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

(2011) E. Bosi et al.   DIABETES OBESITY & METABOLISM

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

(2010) D. Williams-Herman et al.   DIABETES OBESITY & METABOLISM

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

(2010) T. Seck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Severe Hypoglycemia and Risks of Vascular Events and Death

(2010) Sophia Zoungas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

(2009) G. Bolli et al.   DIABETES OBESITY & METABOLISM

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Cardiovascular Outcomes in Trials of Oral Diabetes Medications

(2008) Elizabeth Selvin et al.   ARCHIVES OF INTERNAL MEDICINE

Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin

(2008) B. Göke et al.   HORMONE AND METABOLIC RESEARCH